NSCLC

[Communications Biology] Researchers identified testis-specific Y-like protein 5 (TSPYL5) as an upstream regulator of CSC-associated genes in non-small cell lung cancer cells, and suggested this as a therapeutic target for CSC elimination.

[Cells] The authors critically analyse the mechanisms of epidermal growth factor receptor expression in non-small cell lung cancer (NSCLC), its relevance to currently approved targeted treatment options, and the complex nature of secondary mutations and intrinsic and acquired resistance patterns in NSCLC.

[Turning Point Therapeutics, Inc.] Turning Point Therapeutics, Inc. announced that TPX-0022, the company’s inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R, has been granted orphan drug designation by the Food and Drug Administration (FDA) for the treatment of patients with gastric cancer, including gastroesophageal junction adenocarcinoma.

[Nature] Researchers identified distinct populations of macrophages that were enriched in human and mouse lung tumors.

[Immunology] Scientists performed an integrative analysis of the mutational and transcriptional profiles of large cohorts of non-small-cell lung cancer patients and found that epigenetic downregulation of B2M was common.

[Molecular Therapy-Oncolytics] Scientists conducted dual tumor and T-cell imaging by use of a bioluminescent reporter and positron emission tomography in clinically relevant mouse models of pleural mesothelioma and non-small cell lung cancer.